Immutep Ltd (AU:IMM)
ASX:IMM
Want to see AU:IMM full AI Analyst Report?
IMM Stock Chart & Stats
AU$0.07
-AU$0.01(-2.94%)
At close: 4:00 PM EST
AU$0.07
-AU$0.01(-2.94%)
Day’s Range― - ―
52-Week RangeAU$0.03 - AU$0.47
Previous CloseN/A
Volume844.76K
Average Volume (3M)4.11M
Market Cap
AU$86.95M
Enterprise ValueAU$17.83M
Total Cash (Recent Filing)AU$99.13M
Total Debt (Recent Filing)AU$2.16M
Price to Earnings (P/E)―
Beta2.43
Next Earnings
Sep 02, 2026EPS Estimate
>-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.06
Shares Outstanding1,473,721,300
10 Day Avg. Volume7,757,821
30 Day Avg. Volume4,106,545
Financial Highlights & Ratios
PEG Ratio-0.31
Price to Book (P/B)2.43
Price to Sales (P/S)69.27
P/FCF Ratio-5.63
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$0.17Price Target Upside142.86% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.04
Revenue Forecast (FY)AU$26.73M
Bulls Say, Bears Say
Bulls Say
LAG‑3–focused Clinical PipelineA focused LAG‑3 platform with multiple clinical candidates (eftilagimod alpha, leramilimab and related programs) creates structural R&D optionality. Multiple assets and combination strategies improve program-level probability of value capture and make the company an attractive partner for licensing or co-development over the medium term.
Conservative Balance Sheet / Low LeverageLow leverage reduces solvency and refinancing risk during lengthy clinical programs. A conservative capital structure affords flexibility to time equity raises or execute partnerships from a position of strength, supporting R&D continuity and reducing short‑term liquidity stress relative to highly leveraged peers.
Established Access To Capital Via Collaborations And EquityA proven dual funding model—partner collaborations/milestones plus equity financing—provides recurrent capital channels to fund trials. Structural access to partner funding and investor markets reduces single‑point funding risk and supports multi‑stage clinical development over the next several quarters to years.
Bears Say
Persistent Negative MarginsChronic negative gross, EBIT/EBITDA and net margins reflect a structural inability to generate operating profits in the current business model. Absent successful product commercialization or sustained high‑value partnerships, this forces continued reliance on external capital and limits internal reinvestment capacity.
Ongoing Negative Operating And Free Cash FlowSustained negative operating and free cash flows mean the company cannot self‑fund development and remains exposed to financing timing risk. Even with improving free cash flow growth, persistent cash burn constrains strategic optionality and can delay or downsize programs if external funding is delayed.
Pre‑commercial Revenue ProfileBeing pre‑commercial concentrates execution risk on clinical and regulatory outcomes. Without product sales, long‑term sustainability depends on trial success, milestone/licensing proceeds, or repeated equity raises, which increases dilution risk and creates binary dependency on program progression.
Immutep Ltd News
IMM FAQ
What was Immutep Ltd’s price range in the past 12 months?
Immutep Ltd lowest share price was AU$0.03 and its highest was AU$0.47 in the past 12 months.
What is Immutep Ltd’s market cap?
Immutep Ltd’s market cap is AU$86.95M.
When is Immutep Ltd’s upcoming earnings report date?
Immutep Ltd’s upcoming earnings report date is Sep 02, 2026 which is in 116 days.
How were Immutep Ltd’s earnings last quarter?
Immutep Ltd released its earnings results on Feb 24, 2026. The company reported -AU$0.03 earnings per share for the quarter, missing the consensus estimate of -AU$0.028 by -AU$0.002.
Is Immutep Ltd overvalued?
According to Wall Street analysts Immutep Ltd’s price is currently Undervalued.
Does Immutep Ltd pay dividends?
Immutep Ltd does not currently pay dividends.
What is Immutep Ltd’s EPS estimate?
Immutep Ltd’s EPS estimate is >-0.01.
How many shares outstanding does Immutep Ltd have?
Immutep Ltd has 1,473,721,300 shares outstanding.
What happened to Immutep Ltd’s price movement after its last earnings report?
Immutep Ltd reported an EPS of -AU$0.03 in its last earnings report, missing expectations of -AU$0.028. Following the earnings report the stock price went up 1.299%.
Which hedge fund is a major shareholder of Immutep Ltd?
Currently, no hedge funds are holding shares in AU:IMM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Immutep Ltd Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
AU$0.17 (142.86% Upside)
AU$0.17 (142.86% Upside)
Blogger Sentiment
Bullish
AU:IMM Sentiment 100%
Sector Average 72%
Sector Average 72%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
33.33%
12-Months-Change
Fundamentals
Return on Equity
-69.20%
Trailing 12-Months
Asset Growth
-13.05%
Trailing 12-Months
Company Description
Immutep Ltd
Immutep Limited, a biotechnology company, engages in the research and development of pharmaceutical products. The company develops immunotherapeutic products for the treatment of cancer and autoimmune diseases. Its lead product candidate is eftilagimod alpha (efti or IMP321), a recombinant protein that is in Phase IIb clinical trial as a chemo-immunotherapy combination for metastatic breast cancer. The company also develops TACTI-002, which is in a Phase II clinical trial for the treatment of head and neck squamous cell carcinoma (HNSCC) and non-small cell lung cancer; TACTI-003 that is in Phase IIb clinical trial to treat HNSCC; and INSIGHT-003, which is in a Phase I clinical trial for the treatment of solid tumors, as well as INSIGHT-005 that is in Phase I/IIa clinical trial to treat solid tumors. In addition, it offers IMP761, an agonist of lymphocyte activation gene 3 for autoimmune disease; IMP701, an antagonist antibody that acts to stimulate T cell proliferation in cancer patients; and IMP731, a depleting antibody that removes T cells involved in autoimmunity. Immutep Limited has collaboration agreements with GlaxoSmithKline, Novartis, CYTLIMIC Inc., Merck & Co., Inc., Institute of Clinical Cancer Research, Merck KGaA, and EOC Pharma. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. Immutep Limited was incorporated in 1987 and is headquartered in Sydney, Australia.
IMM Stock 12 Month Forecast
Average Price Target
AU$0.17
▲(142.86% Upside)
Technical Analysis
Imugene
―
Mesoblast Limited
―
Starpharma Holdings Limited
―
Telix Pharmaceuticals
―
Radiopharm Theranostics Limited
―
Options Prices
Currently, No data available
---